My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}

Want to join the conversation?

$KSU {{ '2016-02-09T18:39:47+0000' | timeago}} • SEC

$KSU's revenue for FY15 slid by 6% from last year, due to a 4% decline in revenue per per carload/unit and a 3% decrease in carload/unit volumes. Revenue per carload/unit decreased due to the weakening of the Mexican peso against the U.S. dollar and lower fuel surcharge, resulting from lower U.S. fuel prices.

User Bob Phil {{ '2016-12-08T15:14:43+0000' | timeago}}

$CIEN a good stock to look at for the longs. Consistent revenue increase over the past few quarters suggest steady improvement in profitability of the company, which bodes well for the future prospect. I’m going to add a few more to my portfolio, anticipating good $$$ gains !

User Don Wolters {{ '2016-12-08T00:51:44+0000' | timeago}}

Shareholder alert..!! Rosen Law Firm has commenced an investigation into potential securities claims of $UHS. Shareholders please visit for more info.

User Charles Elliston {{ '2016-12-08T00:03:55+0000' | timeago}}

Can we see "Made in the USA" label on iPhones in the near future? Heard that $AAPL is considering the idea of manufacturing iPhone in America.

User Nora Foster {{ '2016-12-08T00:00:35+0000' | timeago}}

People who are looking for a steady growth stock should take a look at $EME. This stock has never had a significant downfall in the last five years. Comfortably beats consensus target most of the time. Such potential, much wow!

User Amelita Yates {{ '2016-12-07T22:59:16+0000' | timeago}}

Looks like Creative Planning jumped on the bandwagon! Increased its stake by 91% in $EWBC. A lot of companies recently raised their stack too. I smell something’s cooking.

$LLY {{ '2016-12-08T15:58:53+0000' | timeago}} • Announcement

$LLY said the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, met its primary endpoint of reducing expression of Ki67, a biomarker of cell proliferation, after two weeks of treatment of early-stage breast cancer.

$CASY {{ '2016-12-08T15:57:19+0000' | timeago}} • Webcast

During 2Q17, in $CASY’s prepared food category, gross profit dollars rose 7.4% to $156.3MM. The company is optimistic about the growth in this category for the remainder of FY17 as it benefits from the continued implementation of pizza delivery stores and its major remodel program as well as new store openings.

$PBH {{ '2016-12-08T15:54:22+0000' | timeago}} • Announcement

$PBH agreed for sale of the DermoPlast brand to Moberg Pharma AB for $47.6MM in cash plus inventory. The transaction is expected to be completed during December 2016. On an annual basis, $PBH expects the financial impact from the sale of DermoPlast to represent about $12MM in net sales and about $0.06 in EPS.

$CASY {{ '2016-12-08T15:51:15+0000' | timeago}} • Webcast

$CASY's total sales in the grocery and other merchandise category were up 5.5% to $545MM in 2Q17. Same-store sales were up 3.1%. This was short of the annual goal due to a deceleration in customer traffic and a tightening in consumer spending. Total sales across all major areas of the category showed mid to high single digit increases.

$CBT {{ '2016-12-08T15:42:38+0000' | timeago}} • Announcement

$CBT's BoD declared quarterly cash dividend of $0.18 per share on its common stock. The dividend is payable on or about Jan. 30, 2017 to shareholders of record on Dec. 23, 2016.